Nana Kwame Wiredu Amoako is currently fighting for his life against Acute Myeloid Leukaemia (AML), a severe form of cancer.
Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.
Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable ...
Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...
TC BioPharm's Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues ...
PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...
AZoLifeSciences on MSN21d
OGT introduces new NGS SureSeq Myeloid MRD Panel to detect ultra-low frequency MRD-associated biomarkers in AMLThe ultra-sensitive detection of MRD in AML is a critical tool for advancing clinical research in AML. NGS-based AML MRD is being more widely adopted in drug development and studies aiming to improve ...
PLC (NASDAQ: TCBP) shares lost some ground Monday, as the Edinburgh-based clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other ...
The ultra-sensitive detection of MRD in AML is a critical tool for advancing clinical research in AML. NGS-based AML MRD is being more widely adopted in drug development and studies aiming to improve ...
TC BioPharm (NASDAQ: TCBP) has completed full dosing for the first Cohort B patient in its Phase 2B ACHIEVE clinical trial evaluating TCB008 for acut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback